ストックスクリーナーアプリを入手
87.38
4.14%
-3.77
アフターアワーズ：
87.78
0.40
+0.46%
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Early FDA, Japan Filings For Setmelanotide In Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM) - simplywall.st
Wells Fargo Maintains Overweight, Raises Price Target for RYTM t - GuruFocus
Wells Fargo raises Rhythm Pharmaceuticals price target on revenue - Investing.com
598,247 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Purchased by Capital Research Global Investors - MarketBeat
(RYTM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Rhenman & Partners Asset Management AB Purchases Shares of 35,000 Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) CAO Sells $502,789.84 in Stock - MarketBeat
Rhythm Pharmaceuticals (RYTM) Is Down 8.2% After Positive TRANSCEND Data And FDA sNDA Progress - Sahm
Market Recap: Is Rhythm Pharmaceuticals Inc vulnerable to short sellers2025 Trade Ideas & Community Verified Watchlist Alerts - baoquankhu1.vn
Proposed sale of 64,540 common shares under registered plan (RYTM) - Stock Titan
HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat
Rhythm Pharmaceuticals (RYTM) CAO exercises RSUs, withholds shares for taxes - Stock Titan
Jefferies reiterates Rhythm Pharmaceuticals stock rating on trial outlook By Investing.com - Investing.com Canada
RYTM (NASDAQ: RYTM) brokered notice for 35,460-share sale on 03/03/2026 - Stock Titan
Does Rhythm Pharmaceuticals (RYTM) Share Price Reflect Its Obesity Treatment Potential Today - simplywall.st
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright - Yahoo Finance
Analysts Offer Predictions for RYTM FY2027 Earnings - MarketBeat
Rhythm Pharmaceuticals (RYTM) CFO exercises options, acquiring 6,099 shares - Stock Titan
Canaccord Genuity Lowers Price Target for RYTM, Maintains Buy Ra - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $140.00 at Canaccord Genuity Group - MarketBeat
HC Wainwright Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $110.00 - MarketBeat
RYTM: HC Wainwright & Co. Lowers Price Target Despite Maintainin - GuruFocus
Why Is Rhythm Pharmaceuticals Stock Trading Higher Today?Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Robust Analyst Ratings Signal Potential 51.69% Upside - DirectorsTalk Interviews
Canaccord lowers Rhythm Pharmaceuticals stock price target to $140 - Investing.com
Canaccord lowers Rhythm Pharmaceuticals stock price target to $140 By Investing.com - Investing.com Canada
Rhythm Says New Late-Stage Data for Obesity Drug Shows Strong Weight Loss, Hunger Reduction - marketscreener.com
Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity - TipRanks
Rhythm Pharmaceuticals posts 18.8% placebo‑adjusted BMI reduction in TRANSCEND Phase 3 52‑week data - TradingView
Rhythm Pharmaceuticals (Nasdaq: RYTM) adds positive Phase 3 HO data ahead FDA PDUFA - Stock Titan
Rhythm Pharmaceuticals (RYTM) Reveals Promising Phase 3 Trial Da - GuruFocus
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Pullback In Share Price - Yahoo Finance
Rhythm Pharmaceuticals Reports Positive 52-Week Data from Phase 3 TRANSCEND Trial of Setmelanotide for Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals says PDUFA goal date for setmelanotide is March 20, 2026 - marketscreener.com
Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026 - TradingView
Rhythm Pharmaceuticals Announces Additional Positive Data - GlobeNewswire
Artisan Partners Limited Partnership Buys 62,362 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Obesity drug shows 18.8% BMI edge, backing first FDA bid in acquired HO - Stock Titan
RYTM SEC FilingsRhythm Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Rhythm Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-02-27 - Seeking Alpha
Wells Fargo & Company Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $136.00 - MarketBeat
Rhythm Pharmaceuticals (RYTM) Price Target Lowered by Wells Farg - GuruFocus
RBC Capital Adjusts Price Target on Rhythm Pharmaceuticals to $140 From $145, Maintains Outperform Rating - marketscreener.com
Citizens Jmp Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $176.00 - MarketBeat
Is Rhythm Pharmaceuticals Inc. stock risky to hold now2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Needham & Company LLC Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Guggenheim Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
RYTM Stock Update: Guggenheim Maintains 'Buy', Raises Price Targ - GuruFocus
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2025 Earnings Call Transcript - Insider Monkey
Guggenheim raises Rhythm Pharmaceuticals stock price target on guidance By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Citizens raises Rhythm Pharmaceuticals stock price target on HO approval outlook - Investing.com Nigeria
Rhythm Pharmaceuticals (RYTM) Posts Q4 Revenue Gain That Challenges Bearish Cash Burn Narrative - simplywall.st
Decoding Rhythm Pharmaceuticals Inc (RYTM): A Strategic SWOT Ins - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Rhythm Pharmaceuticals files for mixed shelf - marketscreener.com
Rhythm Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Rhythm Pharmaceuticals Inc. (referred to as Rhythm Pharmaceuticals) recently disclosed that some of its shareholders plan to further sell up to 2.4 million shares of common stock. - Bitget
Rhythm Pharmaceuticals Files For Mixed Shelf - TradingView
Rhythm Pharmaceuticals Inc (RYTM) Q4 2025 Earnings Call Highligh - GuruFocus
Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target - Investing.com Nigeria
Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target By Investing.com - Investing.com Australia
Earnings call transcript: Rhythm Pharmaceuticals beats Q4 2025 expectations - Investing.com
Rhythm Pharma Q4 2025 slides: revenue beats as HO launch nears - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Rhythm Pharma (RYTM) Earnings Call Transcript - AOL.com
Westfield Capital Management Co. LP Has $107.96 Million Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (RYTM) Surpasses Revenue Expectations in Q4 - GuruFocus
0.48%
1.21%
大文字化:
|
ボリューム (24 時間):